Sanofi has discontinued development of its next-generation mRNA-based seasonal flu vaccine. According to its 2025 earnings documents, the drugmaker said it halted its phase 1 trial for an mRNA ...
An mRNA influenza vaccine was approximately 35% more effective than an inactivated quadrivalent flu vaccine against two different strains, based on new data from a phase 3 randomized trial. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results